Results 211 to 220 of about 2,864,300 (339)

Does out of Hours Endoscopic Retrograde Cholangiopancreatography Lead to Higher Pancreatitis and Hospitalization Rates?

open access: yesANZ Journal of Surgery, EarlyView.
The aim of this study was to determine if ERCP related morbidity is higher if performed out of workinghours. Contemporaneously collected data patients undergoing ERCP at an Australian hospital were analysed. No difference was found in rates of post‐ERCP pancreatitis (PEP) in patients undergoing out of hours ERCP compared with in hours ERCP (p = 0.759).
Hasib Ahmadzai   +4 more
wiley   +1 more source

Molecular and cellular mechanisms underlying gyrate atrophy: Why is the retina primarily affected?

open access: yesActa Ophthalmologica, EarlyView.
Abstract Gyrate atrophy of the choroid and retina (GACR; OMIM #258870) is a rare early‐onset autosomal recessive disorder, caused by bi‐allelic pathogenic variants in the gene coding for ornithine aminotransferase (OAT) resulting in hyperornithinaemia.
Mark J. N. Buijs   +12 more
wiley   +1 more source

Acute Pancreatitis Associated with an Intraluminal Duodenal Diverticulum

open access: bronze, 1967
Francis C. Nance   +2 more
openalex   +1 more source

Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-Cohort Study in Denmark.

open access: yesGastroenterology, 2018
J. Kirkegård   +3 more
semanticscholar   +1 more source

Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk

open access: yesBritish Journal of Haematology, EarlyView.
Inherited thrombocytopenia (IT) caused by germline variants in RUNX1, ETV6 or ANKRD26 carries a high risk of developing haematological malignancy. This study examined the clinical, platelet and molecular characteristics of 66 patients with these conditions, who carried 24 distinct genetic variants in the corresponding genes.
Ana Marín‐Quílez   +34 more
wiley   +1 more source

Clinical Significance of Low-Density Granulocytes in Acute Pancreatitis. [PDF]

open access: yesMediators Inflamm
Wang J   +11 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy